Feedback
Settings

Settings

Goto Application

1. WO2020111268 - NOVEL CRYSTAL OF (3S)-3-[2-(6-AMINO-2-FLUOROPYRIDINE-3-YL)-4-FLUORO-1H-IMIDAZOLE-5-YL]-7-[5-CHLORO-2-(1H-TETRAZOLE-1-YL)PHENYL]-2,3-DIHYDROINDOLIZINE-5(1H)-ONE

Submit observation
PermaLink
Publication Number WO/2020/111268
Publication Date 04.06.2020
International Application No. PCT/JP2019/046893
International Filing Date 29.11.2019
IPC
A61K 31/444 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non-condensed pyridines; Hydrogenated derivatives thereof
4427containing further heterocyclic ring systems
444containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61P 7/02 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
7Drugs for disorders of the blood or the extracellular fluid
02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
A61P 9/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
9Drugs for disorders of the cardiovascular system
C07D 471/04 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
471Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/-C07D463/251
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
CPC
A61K 31/444
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non condensed pyridines; Hydrogenated derivatives thereof
4427containing further heterocyclic ring systems
444containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
A61K 47/26
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61K 47/38
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
38Cellulose; Derivatives thereof
A61K 9/0019
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
0012Galenical forms characterised by the site of application
0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
A61K 9/0053
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
0012Galenical forms characterised by the site of application
0053Mouth and digestive tract, i.e. intraoral and peroral administration
A61K 9/2013
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
20Pills, tablets, ; discs, rods
2004Excipients; Inactive ingredients
2013Organic compounds, e.g. phospholipids, fats
Applicants
  • 小野薬品工業株式会社 ONO PHARMACEUTICAL CO., LTD. [JP]/[JP]
Inventors
  • 藤戸　貴之 FUJITO, Takayuki
  • 小野　静香 ONO, Shizuka
  • 大谷　修平 OHTANI, Shuhei
Agents
  • 青木　篤 AOKI, Atsushi
  • 三橋　真二 MITSUHASHI, Shinji
  • 渡辺　陽一 WATANABE, Yoichi
  • 中島　勝 NAKAJIMA, Masaru
  • 武居　良太郎 TAKEI, Ryotaro
  • 中村　和美 NAKAMURA, Kazumi
Priority Data
2018-22443430.11.2018JP
Publication Language Japanese (ja)
Filing Language Japanese (JA)
Designated States
Title
(EN) NOVEL CRYSTAL OF (3S)-3-[2-(6-AMINO-2-FLUOROPYRIDINE-3-YL)-4-FLUORO-1H-IMIDAZOLE-5-YL]-7-[5-CHLORO-2-(1H-TETRAZOLE-1-YL)PHENYL]-2,3-DIHYDROINDOLIZINE-5(1H)-ONE
(FR) NOUVEAU CRISTAL DE (3S)-3-[2-(6-AMINO-2-FLUOROPYRIDINE-3-YL)-4-FLUORO-1H-IMIDAZOLE-5-YL]-7-[5-CHLORO-2-(1H-TÉTRAZOLE-1-YL)PHÉNYL]-2,3-DIHYDROINDOLIZINE-5(1H)-ONE
(JA) （３Ｓ）－３－［２－（６－アミノ－２－フルオロピリジン－３－イル）－４－フルオロ－１Ｈ－イミダゾール－５－イル］－７－［５－クロロ－２－（１Ｈ－テトラゾール－１－イル）フェニル］－２，３－ジヒドロインドリジン－５（１Ｈ）－オンの新規結晶
Abstract
(EN) Provided is a novel crystalline form of (3S)-3-[2-(6-amino-2-fluoropyridine-3-yl)-4-fluoro-1h-imidazole-5-yl]-7-[5-chloro-2-(1h-tetrazole-1-yl)phenyl]-2,3-dihydroindolizine-5(1h)-one.　Provided is (3S)-3-[2-(6-amino-2-fluoropyridine-3-yl)-4-fluoro-1h-imidazole-5-yl]-7-[5-chloro-2-(1h-tetrazole-1-yl)phenyl]-2,3-dihydroindolizine-5(1h)-one-3-hydroxy benzoic acid (1/1).
(FR) L'invention concerne une nouvelle forme cristalline de (3S)-3-[2-(6-amino-2-fluoropyridine-3-yl)-4-fluoro-1h-imidazole-5-yl]-7-[5-chloro-2-(1h-tétrazole-1-yl)phényl]-2,3-dihydroindolizine-5(1h)-one.　L'invention porte sur l'acide (3S)-3-[2-(6-amino-2-fluoropyridine-3-yl)-4-fluoro-1h-imidazole-5-yl]-7-[5-chloro-2-(1h-tétrazole-1-yl)phényl]-2,3-dihydroindolizine-5(1h)-one-3-hydroxybenzoïque (1/1).
(JA) （３Ｓ）－３－［２－（６－アミノ－２－フルオロピリジン－３－イル）－４－フルオロ－１Ｈ－イミダゾール－５－イル］－７－［５－クロロ－２－（１Ｈ－テトラゾール－１－イル）フェニル］－２，３－ジヒドロインドリジン－５（１Ｈ）－オンの新規な結晶形態の提供。　（３Ｓ）－３－［２－（６－アミノ－２－フルオロピリジン－３－イル）－４－フルオロ－１Ｈ－イミダゾール－５－イル］－７－［５－クロロ－２－（１Ｈ－テトラゾール－１－イル）フェニル］－２，３－ジヒドロインドリジン－５（１Ｈ）－オン－３－ヒドロキシ安息香酸　（１／１）の提供。
Related patent documents
AU2019390094
MYPI 2021002947
SG11202105697S
CN113226312
KR1020210097119
BR112021010476
JPWO2020111268
EP3888653
US20210395250
IL283481
MXMX/a/2021/006147This application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.
PH1/2021/551219
CA3121447
NZ776666
TH2101003081This application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.
RU2021115277This application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.
Latest bibliographic data on file with the International Bureau
# -